ADCT

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Today, 7:20 AMADC Therapeutics completes enrollment of 100 patients in LOTIS-7 Phase 1b ZYNLONTA + glofitamab trial in relapsed or refractory DLBCL, with data expected Q4 2026

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: IWM VTWO IWN IBB IWC VTWG IWO GWX RSSL IWV

Scroll to Statements

Index	RUT
Market Cap	136.10M
Enterprise Value	21.76M
Income	-136.99M
Sales	79.17M
Book/sh	-1.70
Cash/sh	1.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	193
IPO	May 15, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	1.72
P/B	-
P/C	0.59
P/FCF	-
EV/EBITDA	-
EV/Sales	0.27
Quick Ratio	4.02
Current Ratio	4.09
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.05
EPS next Y	-0.66
EPS next Q	-0.21
EPS this Y	23.93%
EPS next Y	22.24%
EPS next 5Y	37.84%
EPS past 3/5Y	17.66% 21.50%
Sales past 3/5Y	-27.09% -
EPS Y/Y TTM	27.41%
Sales Y/Y TTM	4.43%
EPS Q/Q	40.60%
Sales Q/Q	-9.47%
Earnings	May 04 BMO
EPS/Sales Surpr.	-4.12% 4.32%

Insider Own	23.36%
Insider Trans	-16.52%
Inst Own	57.70%
Inst Trans	1.42%
ROA	-48.57%
ROE	-
ROIC	-
Gross Margin	89.21%
Oper. Margin	-133.00%
Profit Margin	-173.02%
SMA20	-16.42%
SMA50	-60.06%
SMA200	-70.54%
Trades

Shs Outstand	127.17M
Shs Float	97.48M
Short Float	6.16%
Short Ratio	3.33
Short Interest	6.00M
52W High	4.98 -78.51%
52W Low	0.78 37.25%
Volatility	8.47% 12.02%
ATR (14)	0.17
RSI (14)	23.40
Beta	1.92
Rel Volume	0.55
Avg Volume	1.80M
Volume	159,101

Perf Week	-6.96%
Perf Month	-68.53%
Perf Quarter	-70.60%
Perf Half Y	-69.52%
Perf YTD	-69.69%
Perf Year	-60.07%
Perf 3Y	-50.23%
Perf 5Y	-95.61%
Perf 10Y	-
Recom	2.33
Target Price	4.70
Prev Close	1.03
Price	1.07
Change	3.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$2
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Today 07:15AM	ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial (PR Newswire)
Jun-24-26 09:13AM	ADC Therapeutics To Cut About 17% Of Its Staff A Look At Some Key Details (Stocktwits) -6.96%
07:30AM	ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities (PR Newswire)
Jun-04-26 05:27AM	An ADC specialist sinks on safety concerns for blood cancer drug (BioPharma Dive) -57.14%
Jun-03-26 04:05PM	ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PR Newswire)
04:44PM	Loading…
May-04-26 04:44PM	ADC Therapeutics S.A. Q1 2026 Earnings Call Summary (Moby)
07:30AM	ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire)
May-01-26 09:19AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2026 Earnings (GuruFocus.com)
04:05AM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Apr-27-26 07:30AM	ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 (PR Newswire)
Apr-01-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
Mar-10-26 05:01PM	ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +13.48%
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update (PR Newswire)
Mar-09-26 09:17AM	ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
07:15AM	Loading…
Mar-03-26 07:15AM	ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 (PR Newswire)
Mar-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Feb-24-26 07:15AM	ADC Therapeutics to Participate in March Investor Conferences (PR Newswire)
Feb-23-26 07:15AM	ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement (PR Newswire) +7.56%
Feb-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +8.03%
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-13-26 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Jan-08-26 04:05PM	ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
Dec-29-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why (Zacks)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-18-25 01:14AM	RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development (Insider Monkey) +6.27%
Dec-17-25 09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.56%
12:00PM	Loading…
Dec-15-25 12:00PM	ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-04-25 07:40AM	ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma (TipRanks) -10.38%
Dec-03-25 07:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -14.13%
Dec-02-25 04:05PM	ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial (PR Newswire) +8.49%
Dec-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-18-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-25 04:01PM	ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... (GuruFocus.com) -5.70%
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
07:20AM	ADC Therapeutics SA (ADCT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.28%
07:15AM	ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 (PR Newswire)
Oct-27-25 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Oct-26-25 06:16AM	ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted (Insider Monkey)
Oct-24-25 08:07AM	H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement (Insider Monkey)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
07:30AM	ADC Therapeutics Announces $60 Million Private Placement (PR Newswire)
Oct-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Sep-29-25 12:56AM	ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion (Insider Monkey) +10.14%
Sep-18-25 10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +6.13%
Aug-27-25 07:15AM	ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 03:07AM	ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) +5.10%
Aug-12-25 03:00PM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.70%
07:30AM	ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Aug-11-25 07:00PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:34AM	ADC Therapeutics SA (ADCT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 04:05PM	ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 (PR Newswire)
Aug-04-25 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Aug-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Jul-01-25 04:05PM	ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-16-25 07:15AM	ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire) -5.59%
Jun-12-25 06:45AM	ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PR Newswire)
06:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress (PR Newswire)
Jun-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +13.59%
May-30-25 05:44AM	AbbVies ADC win shows how pharma can break through in solid tumors (Pharma Voice) +11.55%
May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%
Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

M.S.Dr. Ameet Mallik M.B.A.

Chief Financial OfficerMr. Jose I. Carmona M.B.A.

Ph.D.Dr. Mohamed Zaki M.D.

Corporate Controller & Chief Accounting OfficerMs. Lisa Michelle Kallebo

Chief Technical OfficerDr. David S. Ege Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Apr 02 '26	Sale	3.28	2,634,506	8,638,545	12,666,731	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 02 '26	Sale	3.28	2,529,491	8,294,201	10,265,297	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Mar 31 '26	Sale	3.75	196,229	736,251	15,470,502	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Mar 31 '26	Sale	3.75	188,407	706,903	12,957,305	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 01 '26	Sale	3.80	169,265	643,038	15,301,237	Apr 02 09:00 PM
Redmile Group, LLC	10% Owner	Apr 01 '26	Sale	3.80	162,517	617,402	12,794,788	Apr 02 09:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Adc Therapeutics SA

Upgrade your Finviz experience